Growth Metrics

Ultragenyx Pharmaceutical (RARE) Interest Expenses (2013 - 2014)

Ultragenyx Pharmaceutical (RARE) reported Interest Expenses of $73000.0 for Q2 2014, down 82.02% year-over-year from $406000.0 in Q2 2013, and down 97.84% on a QoQ basis from $3.4 million in Q1 2014.

Ultragenyx Pharmaceutical (RARE) has 2 years of Interest Expenses data on file, last reported at $73000.0 in Q2 2014.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Expense (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 22,854.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -5.50 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 61,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -332,000.00
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 12.90 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 69.29 Mn
10 Ultragenyx Pharmaceutical 2.29 Bn 1.89 Bn 106.00 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2014 73,000.00
Jun 30, 2014 73,000.00
Mar 31, 2014 3.38 Mn
Mar 31, 2014 3.38 Mn
Jun 30, 2013 406,000.00
Jun 30, 2013 406,000.00
Mar 31, 2013 14,000.00
Mar 31, 2013 14,000.00